39 related articles for article (PubMed ID: 38626371)
1. Single-Inhaler Triple versus Dual Bronchodilator Therapy in COPD: Real-World Comparative Effectiveness and Safety.
Suissa S; Dell'Aniello S; Ernst P
Int J Chron Obstruct Pulmon Dis; 2022; 17():1975-1986. PubMed ID: 36065315
[TBL] [Abstract][Full Text] [Related]
2. Clinical Characteristics, Treatment Persistence, and Outcomes Among Patients With COPD Treated With Single- or Multiple-Inhaler Triple Therapy: A Retrospective Analysis in Spain.
Alcázar-Navarrete B; Jamart L; Sánchez-Covisa J; Juárez M; Graefenhain R; Sicras-Mainar A
Chest; 2022 Nov; 162(5):1017-1029. PubMed ID: 35787391
[TBL] [Abstract][Full Text] [Related]
3. Author Reply to Commentary: Don't miss the forest for the trees.
Roselli EE
J Thorac Cardiovasc Surg; 2024 Jun; 167(6):2062. PubMed ID: 36610882
[No Abstract] [Full Text] [Related]
4. Optimizing Pharmacotherapy Management of COPD: Don't Miss the Forest for the Trees.
Bourbeau J; Bhutani M; Hernandez P; Penz E; Marciniuk DD
Am J Respir Crit Care Med; 2024 Apr; ():. PubMed ID: 38626371
[No Abstract] [Full Text] [Related]
5. Interventions to improve adherence to pharmacological therapy for chronic obstructive pulmonary disease (COPD).
Janjua S; Pike KC; Carr R; Coles A; Fortescue R; Batavia M
Cochrane Database Syst Rev; 2021 Sep; 9(9):CD013381. PubMed ID: 34496032
[TBL] [Abstract][Full Text] [Related]
6. The Impact of 52-Week Single Inhaler Device Triple Therapy versus Dual Therapy on the Mortality of COPD Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Lai CC; Chen CH; Chen KH; Wang CY; Huang TM; Wang YH; Wang HC
Life (Basel); 2022 Jan; 12(2):. PubMed ID: 35207460
[TBL] [Abstract][Full Text] [Related]
7. Management of chronic obstructive pulmonary disease: A review focusing on exacerbations.
Bollmeier SG; Hartmann AP
Am J Health Syst Pharm; 2020 Feb; 77(4):259-268. PubMed ID: 31930287
[TBL] [Abstract][Full Text] [Related]
8. Single-inhaler triple therapy utilizing the once-daily combination of fluticasone furoate, umeclidinium and vilanterol in the management of COPD: the current evidence base and future prospects.
Malerba M; Nardin M; Santini G; Mores N; Radaeli A; Montuschi P
Ther Adv Respir Dis; 2018; 12():1753466618760779. PubMed ID: 29537340
[TBL] [Abstract][Full Text] [Related]
9. Current appraisal of single inhaler triple therapy in COPD.
Lipworth B; Kuo CR; Jabbal S
Int J Chron Obstruct Pulmon Dis; 2018; 13():3003-3009. PubMed ID: 30319248
[TBL] [Abstract][Full Text] [Related]
10. Innovations to achieve excellence in COPD diagnosis and treatment in primary care.
Fromer L; Barnes T; Garvey C; Ortiz G; Saver DF; Yawn B
Postgrad Med; 2010 Sep; 122(5):150-64. PubMed ID: 20861599
[TBL] [Abstract][Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
